Skip to main content
. Author manuscript; available in PMC: 2023 Dec 5.
Published in final edited form as: J Card Fail. 2023 Jun 17;29(8):1113–1120. doi: 10.1016/j.cardfail.2023.04.015

Table 1.

Incidence of HF hospitalization by severity and treatment effect of vericiguat

Outcome Vericiguat (n = 2526)
 Placebo (n = 2524)
 HR (95% CI)* P Value*
No. events (%) no. pts Events/100 pt-yrs No. events (%) no. pts Events/100 pt-yrs
Total CEC HF events 1402 (28.9)730 43.94 1546 (31.5) 795 49.06 0.90 (0.83–0.98) 0.010
Urgent HF visit 179 (4.5) 114 5.61 210 (5.0) 126 6.66 0.85 (0.69–1.04) 0.107
Total hospitalizations for HF 1223 (27.4)691 38.33 1336 (29.6) 747 42.40 0.91 (0.84–0.99) 0.025
HFH with oral intensification of diuretics only 38 (1.3) 33 1.19 30 (1.1)29 0.95 1.26 (0.78–2.03) 0.348
HFH with IV diuretics only 766 (19.4) 490 24.01 846 (21.1) 533 26.85 0.90 (0.81–0.99) 0.037
HFH with IV vasodilators 72 (2.5) 63 2.26 85 (2.7) 69 2.70 0.83 (0.61–1.14) 0.257
HFH with IV inotropes 242 (7.0) 177 7.58 280 (8.6)216 8.89 0.86 (0.73–1.03) 0.100
HFH with mechanical circulatory support or fluid removal 102 (3.6)91 3.20 94 (2.8)71 2.98 1.09 (0.82–1.44) 0.552
*

Hazard ratio (95% CI) and P value computed from a stratified Andersen-Gill model.CEC, clinical events committee; CI, confidence interval; HF, heart failure; HFH, heart failure hospitalization; HR, hazard ratio; IV, intravenous; pt, patients; pt-yrs, patient years.